Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: An immunohistochemical and RT-PCR study

Fausto J Rodriguez, Bernd W. Scheithauer, Federico Roncaroli, Ana I. Silva, Kalman Kovacs, Daniel J. Brat, Long Jin

Research output: Contribution to journalArticle

Abstract

Galectin-3 expression has been reported in spindle cell oncocytoma, certain pituitary adenoma subtypes, astrocytomas, oligodendrogliomas, and meningiomas. We evaluated galectin-3 protein expression by immunohistochemistry in 201 cases of a variety of nervous system and sellar tumors, as well as mRNA expression by reverse transcription-polymerase chain reaction in formalin-fixed paraffin-embedded tissue in a subset (20 cases). Immunohistochemical results were evaluated in a semiquantitative fashion on a 4-tiered scale (0 to 3). Strong (3+) immunoreactivity was seen in most of the cases (61%), followed by 2+(22%), and 1+(13%) staining. Only 4% of the lesions studied were immunonegative. Galectin-3 mRNA was present in 15 of the 18 cases (83%) in which reverse transcription-polymerase chain reaction was successful. Significant differences in protein expression were noted in the following 2 settings: specific meningioma subtypes (P=0.004, Fisher exact test) wherein clear cell meningioma demonstrated weak protein expression when compared with other meningioma variants. No significant difference was noted with respect to World Health Organization grade. Galectin-3 was also strongly expressed in benign nerve sheath tumors but only moderately expressed in malignant peripheral nerve sheath tumors (P=0.0009, Fisher exact test). Although galectin-3 positivity is a key feature of the immunophenotype of spindle cell oncocytoma, its consistent expression in other morphologically similar tumors (meningioma, pituicytoma, nerve sheath tumors, granular cell tumor, metastases) makes it of little use in the differential diagnosis of sellar region tumors, a setting in which it should be discouraged. Diagnostic uses of this marker may be limited to specific settings, including some meningioma subtypes and nerve sheath tumors.

Original languageEnglish (US)
Pages (from-to)1344-1352
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume32
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Galectin 3
Meningioma
Nervous System
Nerve Sheath Neoplasms
Polymerase Chain Reaction
Oxyphilic Adenoma
Neoplasms
Reverse Transcription
Nervous System Neoplasms
Granular Cell Tumor
Oligodendroglioma
Messenger RNA
Proteins
Neurilemmoma
Astrocytoma
Pituitary Neoplasms
Paraffin
Formaldehyde
Differential Diagnosis
Immunohistochemistry

Keywords

  • Differential diagnosis
  • Galectin-3
  • Immunohistochemistry
  • Nervous system
  • RT-PCR
  • Sella
  • Tumor

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery
  • Medicine(all)

Cite this

Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics : An immunohistochemical and RT-PCR study. / Rodriguez, Fausto J; Scheithauer, Bernd W.; Roncaroli, Federico; Silva, Ana I.; Kovacs, Kalman; Brat, Daniel J.; Jin, Long.

In: American Journal of Surgical Pathology, Vol. 32, No. 9, 09.2008, p. 1344-1352.

Research output: Contribution to journalArticle

Rodriguez, Fausto J ; Scheithauer, Bernd W. ; Roncaroli, Federico ; Silva, Ana I. ; Kovacs, Kalman ; Brat, Daniel J. ; Jin, Long. / Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics : An immunohistochemical and RT-PCR study. In: American Journal of Surgical Pathology. 2008 ; Vol. 32, No. 9. pp. 1344-1352.
@article{fe71baed5d374d7e9de21fae71dfb9b2,
title = "Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics: An immunohistochemical and RT-PCR study",
abstract = "Galectin-3 expression has been reported in spindle cell oncocytoma, certain pituitary adenoma subtypes, astrocytomas, oligodendrogliomas, and meningiomas. We evaluated galectin-3 protein expression by immunohistochemistry in 201 cases of a variety of nervous system and sellar tumors, as well as mRNA expression by reverse transcription-polymerase chain reaction in formalin-fixed paraffin-embedded tissue in a subset (20 cases). Immunohistochemical results were evaluated in a semiquantitative fashion on a 4-tiered scale (0 to 3). Strong (3+) immunoreactivity was seen in most of the cases (61{\%}), followed by 2+(22{\%}), and 1+(13{\%}) staining. Only 4{\%} of the lesions studied were immunonegative. Galectin-3 mRNA was present in 15 of the 18 cases (83{\%}) in which reverse transcription-polymerase chain reaction was successful. Significant differences in protein expression were noted in the following 2 settings: specific meningioma subtypes (P=0.004, Fisher exact test) wherein clear cell meningioma demonstrated weak protein expression when compared with other meningioma variants. No significant difference was noted with respect to World Health Organization grade. Galectin-3 was also strongly expressed in benign nerve sheath tumors but only moderately expressed in malignant peripheral nerve sheath tumors (P=0.0009, Fisher exact test). Although galectin-3 positivity is a key feature of the immunophenotype of spindle cell oncocytoma, its consistent expression in other morphologically similar tumors (meningioma, pituicytoma, nerve sheath tumors, granular cell tumor, metastases) makes it of little use in the differential diagnosis of sellar region tumors, a setting in which it should be discouraged. Diagnostic uses of this marker may be limited to specific settings, including some meningioma subtypes and nerve sheath tumors.",
keywords = "Differential diagnosis, Galectin-3, Immunohistochemistry, Nervous system, RT-PCR, Sella, Tumor",
author = "Rodriguez, {Fausto J} and Scheithauer, {Bernd W.} and Federico Roncaroli and Silva, {Ana I.} and Kalman Kovacs and Brat, {Daniel J.} and Long Jin",
year = "2008",
month = "9",
doi = "10.1097/PAS.0b013e3181694f41",
language = "English (US)",
volume = "32",
pages = "1344--1352",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Galectin-3 expression is ubiquitous in tumors of the sellar region, nervous system, and mimics

T2 - An immunohistochemical and RT-PCR study

AU - Rodriguez, Fausto J

AU - Scheithauer, Bernd W.

AU - Roncaroli, Federico

AU - Silva, Ana I.

AU - Kovacs, Kalman

AU - Brat, Daniel J.

AU - Jin, Long

PY - 2008/9

Y1 - 2008/9

N2 - Galectin-3 expression has been reported in spindle cell oncocytoma, certain pituitary adenoma subtypes, astrocytomas, oligodendrogliomas, and meningiomas. We evaluated galectin-3 protein expression by immunohistochemistry in 201 cases of a variety of nervous system and sellar tumors, as well as mRNA expression by reverse transcription-polymerase chain reaction in formalin-fixed paraffin-embedded tissue in a subset (20 cases). Immunohistochemical results were evaluated in a semiquantitative fashion on a 4-tiered scale (0 to 3). Strong (3+) immunoreactivity was seen in most of the cases (61%), followed by 2+(22%), and 1+(13%) staining. Only 4% of the lesions studied were immunonegative. Galectin-3 mRNA was present in 15 of the 18 cases (83%) in which reverse transcription-polymerase chain reaction was successful. Significant differences in protein expression were noted in the following 2 settings: specific meningioma subtypes (P=0.004, Fisher exact test) wherein clear cell meningioma demonstrated weak protein expression when compared with other meningioma variants. No significant difference was noted with respect to World Health Organization grade. Galectin-3 was also strongly expressed in benign nerve sheath tumors but only moderately expressed in malignant peripheral nerve sheath tumors (P=0.0009, Fisher exact test). Although galectin-3 positivity is a key feature of the immunophenotype of spindle cell oncocytoma, its consistent expression in other morphologically similar tumors (meningioma, pituicytoma, nerve sheath tumors, granular cell tumor, metastases) makes it of little use in the differential diagnosis of sellar region tumors, a setting in which it should be discouraged. Diagnostic uses of this marker may be limited to specific settings, including some meningioma subtypes and nerve sheath tumors.

AB - Galectin-3 expression has been reported in spindle cell oncocytoma, certain pituitary adenoma subtypes, astrocytomas, oligodendrogliomas, and meningiomas. We evaluated galectin-3 protein expression by immunohistochemistry in 201 cases of a variety of nervous system and sellar tumors, as well as mRNA expression by reverse transcription-polymerase chain reaction in formalin-fixed paraffin-embedded tissue in a subset (20 cases). Immunohistochemical results were evaluated in a semiquantitative fashion on a 4-tiered scale (0 to 3). Strong (3+) immunoreactivity was seen in most of the cases (61%), followed by 2+(22%), and 1+(13%) staining. Only 4% of the lesions studied were immunonegative. Galectin-3 mRNA was present in 15 of the 18 cases (83%) in which reverse transcription-polymerase chain reaction was successful. Significant differences in protein expression were noted in the following 2 settings: specific meningioma subtypes (P=0.004, Fisher exact test) wherein clear cell meningioma demonstrated weak protein expression when compared with other meningioma variants. No significant difference was noted with respect to World Health Organization grade. Galectin-3 was also strongly expressed in benign nerve sheath tumors but only moderately expressed in malignant peripheral nerve sheath tumors (P=0.0009, Fisher exact test). Although galectin-3 positivity is a key feature of the immunophenotype of spindle cell oncocytoma, its consistent expression in other morphologically similar tumors (meningioma, pituicytoma, nerve sheath tumors, granular cell tumor, metastases) makes it of little use in the differential diagnosis of sellar region tumors, a setting in which it should be discouraged. Diagnostic uses of this marker may be limited to specific settings, including some meningioma subtypes and nerve sheath tumors.

KW - Differential diagnosis

KW - Galectin-3

KW - Immunohistochemistry

KW - Nervous system

KW - RT-PCR

KW - Sella

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=52149115131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52149115131&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e3181694f41

DO - 10.1097/PAS.0b013e3181694f41

M3 - Article

C2 - 18670355

AN - SCOPUS:52149115131

VL - 32

SP - 1344

EP - 1352

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 9

ER -